Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HOWL | US
0.00
0.23%
Healthcare
Biotechnology
30/06/2024
15/04/2026
0.92
0.92
0.94
0.88
Werewolf Therapeutics Inc. a biopharmaceutical company develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company through its proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124 a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330 a conditionally activated Interleukin-12 INDUKINE molecule which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898 a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712 an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics Inc. was incorporated in 2017 and is headquartered in Watertown Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
111.1%1 month
100.0%3 months
95.0%6 months
105.5%-
-
0.86
0.35
0.24
0.57
0.67
-
-56.51M
40.19M
40.19M
-
-1.66K
-
-85.90
-48.27
7.94
4.06
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.39
Range3M
0.61
Rel. volume
0.28
Price X volume
80.60K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.67 | 43.86M | 1.52% | n/a | 118.63% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 1.09 | 43.74M | 11.75% | n/a | 2.71% |
| Cue Biopharma Inc | CUE | Biotechnology | 0.7243 | 43.61M | 65.37% | n/a | 52.09% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 6.18 | 43.22M | 5.28% | n/a | -194.60% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.18 | 42.86M | 4.42% | n/a | 3.91% |
| BioXcel Therapeutics Inc | BTAI | Biotechnology | 1.05 | 42.78M | -0.94% | n/a | -139.46% |
| Audentes Therapeutics Inc | BOLD | Biotechnology | 1.63 | 42.70M | 4.49% | n/a | 0.47% |
| CIBUS GLOBAL LTD. | CBUS | Biotechnology | 1.44 | 42.47M | 1.41% | n/a | 81.33% |
| Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.26 | 39.25M | 14.55% | n/a | 4.22% |
| SABS | SABS | Biotechnology | 4.05 | 37.38M | 4.92% | n/a | 11.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.72 | 20.90M | -6.98% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6299 | 12.17M | 1.11% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6947 | 10.15M | -23.66% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3631 | 3.48M | 3.27% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.231 | 2.20M | 7.49% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.74 | 958.74K | -6.95% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.005 | 461.07K | 0.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | - | Par |
| Ent. to Revenue | 0.67 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 94.99 | - | Riskier |
| Debt to Equity | 0.35 | -1.23 | Expensive |
| Debt to Assets | 0.24 | 0.25 | Par |
| Market Cap | 40.19M | - | Emerging |